Brainomix - Version e-ILD - AI-Powered Solution for Assessment of Interstitial Lung Disease (ILD)
There is a growing need for more accurate and reproducible assessment and quantification of Interstitial Lung Disease. Brainomix’ e-ILD solution has been trained to characterize and quantify pulmonary fibrosis and other characteristics using thousands of cases from leading academic institutions. Automated biomarkers such as those available through e-ILD have been shown to correlate with mortality, and to predict changes in FVC at earlier timepoints.
AI-powered biomarkers from e-ILD are available now for use in clinical trials, and can support:
- Efficacy measurement as an adjunct to traditional functional measures such as FVC
- Enrichment of trial cohort with progressive fibrosis phenotype
- Reduced sample sizes and faster trial execution